Parkinson's disease, Dopamine, Internal medicine, Endocrinology and Central nervous system disease are his primary areas of study. His studies in Parkinson's disease integrate themes in fields like Neuroscience and Parkinsonism. The concepts of his Parkinsonism study are interwoven with issues in Mutation and Missense mutation.
A. Jon Stoessl combines topics linked to Neurotransmitter with his work on Dopamine. His research in Internal medicine is mostly concerned with Disease. A. Jon Stoessl combines subjects such as Catecholamine and Dopamine agonist with his study of Central nervous system disease.
A. Jon Stoessl mainly focuses on Parkinson's disease, Dopamine, Internal medicine, Neuroscience and Endocrinology. His research investigates the connection with Parkinson's disease and areas like Central nervous system disease which intersect with concerns in Transplantation and Urology. A. Jon Stoessl studied Dopamine and Levodopa that intersect with Catecholamine.
His Internal medicine research includes themes of Methylphenidate and Oncology. His research investigates the connection between Endocrinology and topics such as Agonist that intersect with issues in Tachykinin receptor. His Parkinsonism study integrates concerns from other disciplines, such as Genetics, Dementia and Missense mutation.
The scientist’s investigation covers issues in Parkinson's disease, Disease, Dopamine, Dopaminergic and Internal medicine. He works mostly in the field of Parkinson's disease, limiting it down to topics relating to Glial cell line-derived neurotrophic factor and, in certain cases, Anesthesia, Unified Parkinson's disease rating scale, Randomization and Clinical endpoint. While the research belongs to areas of Disease, he spends his time largely on the problem of Intensive care medicine, intersecting his research to questions surrounding Neurology, Therapeutic strategy, Dyskinesia and Levodopa therapy.
Dopamine is often connected to Levodopa in his work. His Internal medicine research incorporates themes from White matter, Endocrinology, Lesion, Oncology and Cardiology. His Endocrinology study combines topics from a wide range of disciplines, such as Serotonergic and LRRK2.
A. Jon Stoessl mainly investigates Parkinson's disease, Disease, Dopamine, Neuroscience and Striatum. The Parkinson's disease study combines topics in areas such as Glial cell line-derived neurotrophic factor and Urology. His Disease research is multidisciplinary, incorporating perspectives in Biomarker, Clinical trial and Intensive care medicine.
Internal medicine and Endocrinology are the areas that his Dopamine study falls under. His work in the fields of Internal medicine, such as LRRK2 and Cholinergic, overlaps with other areas such as Acetylcholinesterase. His research investigates the connection between Striatum and topics such as Dopaminergic that intersect with problems in Neurodegeneration and Movement disorders.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Alexander Zimprich;Alexander Zimprich;Saskia Biskup;Petra Leitner;Peter Lichtner.
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease†
C. Warren Olanow;Christopher G. Goetz;Jeffrey H. Kordower;A. Jon Stoessl.
Annals of Neurology (2003)
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
Raúl de la Fuente-Fernández;Thomas J. Ruth;Vesna Sossi;Michael Schulzer.
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
Anthony E. Lang;Steven Gill;Nik K. Patel;Andres Lozano.
Annals of Neurology (2006)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Alan L Whone;Ray L Watts;A Jon Stoessl;Margaret Davis.
Annals of Neurology (2003)
Double-blind study of botulinum toxin in spasmodic torticollis
JosephK.C Tsui;A Jon Stoessl;Andrew Eisen;Susan Calne.
The Lancet (1986)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J Marks;Jill L Ostrem;Leonard Verhagen;Philip A Starr.
Lancet Neurology (2008)
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease
Silke Appel-Cresswell;Carles Vilarino-Guell;Mary Encarnacion;Holly Sherman.
Movement Disorders (2013)
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Chong S. Lee;Ali Samii;Vesna Sossi;Thomas J. Ruth.
Annals of Neurology (2000)
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
Raúl de la Fuente-Fernández;Vesna Sossi;Zhigao Huang;Sarah Furtado.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: